Adam Kern
Overview
Explore the profile of Adam Kern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kern A, Stompor T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak K, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767578
Background: This study aimed to characterize acute coronary syndrome (ACS) patients undergoing invasive diagnostics and to evaluate prognostic factors for all-cause mortality over a 10-year follow-up period. Methods: The KORONEF...
2.
Kubica J, Adamski P, Ostrowska M, Kubica A, Gajda R, Badariene J, et al.
Int J Cardiol
. 2024 Dec;
421():132897.
PMID: 39647786
De-escalation of dual antiplatelet (DAPT) intensity may be considered in patients with high risk of bleeding after acute coronary syndrome. Some high risk patients after de-escalation may require antithrombotic therapy...
3.
Kern A, Stompor T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak K, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458108
We aimed to explore the predictive role of soluble urokinase plasminogen activator receptor (suPAR) in patients undergoing coronary angiography by systematically evaluating its association with adverse cardiovascular events at 10...
4.
Adamski P, Skonieczny G, Hajdukiewicz T, Kern A, Kubica J
Rev Cardiovasc Med
. 2024 Jul;
23(9):300.
PMID: 39077695
Antiplatelet treatment is one of the pillars of contemporary therapy in acute coronary syndromes. It is based on dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor....
5.
Bil J, Buller P, Gil R, Gromadzinski L, Onichimowski D, Jalali R, et al.
Rev Cardiovasc Med
. 2024 Jul;
23(12):393.
PMID: 39076651
Background: Recently, we have observed an increasing focus on myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) patients. MINOCA incidence is estimated to be within the range of 5-15% of...
6.
Kern A, Stompor T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak D, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38929903
We aimed to characterize the population of consecutive patients undergoing coronary angiography with simultaneous renal artery angiography and assess prognostic factors at a 10 year follow-up. The KORONEF study was...
7.
Bil J, Tyczynski M, Kern A, Bojko K, Gil R
J Cardiovasc Dev Dis
. 2024 Jun;
11(6).
PMID: 38921660
We characterized the performance, as well as the safety, of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), implanted in patients with type 2 diabetes...
8.
Kern A, Pawlak S, Poskrobko G, Bojko K, Gromadzinski L, Onichimowski D, et al.
Cardiol J
. 2024 Jun;
31(5):647-655.
PMID: 38832552
Background: The COVID-19 pandemic has impacted many acute coronary syndrome (ACS) care aspects. The aim was to compare the patient profile, ACS characteristics, and the outcomes in patients referred to...
9.
Gil R, Kern A, Bojko K, Gziut-Rudkowska A, Vassilev D, Bil J
Biomedicines
. 2024 May;
12(5).
PMID: 38790900
This multicenter, randomized study aimed to compare the sirolimus-eluting BiOSS LIM C dedicated coronary bifurcation stent with second-generation -limus drug-eluting stents (rDESs) in the treatment of non-left main (non-LM) coronary...
10.
Jalali R, Zwiernik J, Rotkiewicz E, Zwiernik B, Kern A, Bil J, et al.
J Pers Med
. 2024 Jan;
14(1).
PMID: 38248781
Background: Ischemic stroke is one of the leading causes of mortality and disability. The neuroimaging methods are the gold standard for diagnostics. Biomarkers of cerebral ischemia are considered to be...